Ipsen, an innovation-driven global specialty pharmaceutical group, announced that Dysport is now available in the United States for the treatment of cervical dystonia in adults. Dysport is the latest addition to the growing range of Ipsen’s drugs already available in North America, both in endocrinology with Somatuline Depot and Increlex, and in neurology, with Apokyn.
The details can be read here.
No comments:
Post a Comment